Evotec AG (ETR:EVT) received a €14.00 ($16.47) price objective from analysts at Oddo Securities in a research report issued on Friday. The brokerage currently has a “neutral” rating on the stock.

Several other equities analysts have also recently issued reports on the company. Berenberg Bank set a €13.00 ($15.29) price objective on Evotec AG and gave the company a “neutral” rating in a research note on Thursday. Deutsche Bank AG set a €16.00 ($18.82) target price on Evotec AG and gave the stock a “buy” rating in a research note on Monday.

Evotec AG (ETR:EVT) opened at 14.30 on Friday. The stock’s 50 day moving average is €13.26 and its 200 day moving average is €10.71. The firm has a market cap of €2.00 billion and a P/E ratio of 56.52. Evotec AG has a 12-month low of €4.20 and a 12-month high of €14.65.

WARNING: This article was first reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.watchlistnews.com/evotec-ag-etrevt-given-a-14-00-price-target-by-oddo-securities-analysts/1472592.html.

About Evotec AG

Evotec AG provides drug discovery solutions to the pharmaceutical and biotechnology companies, academic institutions, and foundations and not-for-profit organizations worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as integrated services, target identification and validation, hit identification, compound management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, cell and protein production, and in vivo and in vitro pharmacology services.

Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with Analyst Ratings Network's FREE daily email newsletter.